Security key
M0740A108
Alpha Tau Medical Ltd. - Ordinary Shares, no par value (DRTS)
CUSIP: M0740A108
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Ordinary Shares, no par value
- Total 13F shares
- 655,424
- Total 13F value
- $8,312,602
- Share change
- +59,639
- SEC-reported price per share
- $12.58
- Number of holders
- 14
- Value change
- +$750,623
- Number of buys
- 6
- Shares outstanding
- 86,723,804
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
14
Top holders
10
DRTS full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q3 2025
Alpha Tau Medical Ltd. SEC filings
Alpha Tau Medical Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M0740A108
Recent filing periods:
Ownership snapshot
Top reported holders of DRTS - Alpha Tau Medical Ltd. - Ordinary Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORAMED PHARMACEUTICALS INC.
Disclosed value leader
Uzi Sofer
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 20%
13D/G row: ORAMED PHARMACEUTICALS INC.
Showing 1-6 of 15 holder rows.
Quick read
ORAMED PHARMACEUTICALS INC. leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORAMED PHARMACEUTICALS INC.'s linked filing trail.
Comparable ownership
Top 5
ORAMED PHARMACEUTICALS INC.
20%
Uzi Sofer
16%
HighTower Advisors, LLC
1%
Aquamarine Financial (Cayman) Ltd
0.83%
Apella Capital, LLC
0.44%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. |
13D/G
|
20%
|
$37,250,719
14,110,121 shares
|
$0 | 24 Apr 2025 |
| Uzi Sofer |
13D/G
3/4/5
Chief Executive Officer, Director
|
16%
|
$42,751,366
13,702,361 shares
|
$0 | 31 Dec 2022 |
| HighTower Advisors, LLC |
13F
Company
|
1%
|
$6,186,208
874,994 shares
|
— | 31 Mar 2026 |
| Aquamarine Financial (Cayman) Ltd |
13F
Company
|
0.83%
|
$5,101,012
721,501 shares
|
— | 31 Mar 2026 |
| Apella Capital, LLC |
13F
Company
|
0.44%
|
$3,069,741
382,284 shares
|
— | 31 Mar 2026 |
| ARK Investment Management LLC |
13F
Company
|
0.34%
|
$2,065,387
292,134 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
14
Shares
655,424
Rows available
14
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q3 2025 Across Filers
Q3 2025 holders
31
Q2 2026 holders
14
Holder diff
-17
| Investor | Q3 2025 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q3 2025 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend